- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- Fasudil (WP-0512)
- Drug
- Lead sponsor
- Woolsey Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • Aurora, Colorado • Denver, Colorado + 6 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 289–312
of 7,434
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Oligometastatic Disease, Liver Metastases, Colorectal Cancer
- Interventions
- Gadoxetate disodium, Gadobenate dimeglumine
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Lung Cancer
- Interventions
- Patient nudge
- Behavioral
- Lead sponsor
- Kaiser Permanente
- Other
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 894 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Blepharitis
- Interventions
- Pimecrolimus 0.3% Ophthalmic Ointment, Placebo Ophthalmic Ointment
- Drug
- Lead sponsor
- Famy Life Sciences, a Viatris Company
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 477 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 29
- States / cities
- Pheonix, Arizona • Garden Grove, California • Glendale, California + 26 more
- Conditions
- Recurrent Uterine Corpus Sarcoma, Uterine Corpus Leiomyosarcoma
- Interventions
- Ixabepilone, Laboratory Biomarker Analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 72
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 54 more
- Conditions
- Colorectal Cancer
- Interventions
- FOLFOX (chemotherapy), 5 FUCMT (chemoradiation), surgery, magnetic resonance imaging or endorectal ultrasound
- Drug · Other · Procedure
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,194 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2024
- U.S. locations
- 1048
- States / cities
- Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 613 more
- Conditions
- Sickle Cell Disease
- Interventions
- Etavopivat, Placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 510 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 49
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 37 more
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms
- Interventions
- EPO906 (Patupilone), doxorubicin
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 829 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 104
- States / cities
- Anchorage, Alaska • Flagstaff, Arizona • Scottsdale, Arizona + 82 more
- Conditions
- Primary Sclerosing Cholangitis
- Interventions
- Seladelpar, Placebo to match Seladelpar
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 8
- States / cities
- San Francisco, California • Aurora, Colorado • Miami, Florida + 5 more
- Conditions
- Breast Carcinoma
- Interventions
- Electronic Health Record Review, Health Promotion and Education, Health Telemonitoring, Patient Navigation, Survey Administration, Text Message-Based Navigation Intervention
- Other · Procedure · Behavioral
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 390 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 499
- States / cities
- Fairbanks, Alaska • Kingman, Arizona • Phoenix, Arizona + 338 more
- Conditions
- Liver Disease
- Interventions
- HepQuant-SHUNT (Drug and Device) #65,123 (4D-cholate) and IND #65,121 (13C-cholate), Hepatic Venous Pressure Gradient (HVPG)
- Drug · Device
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Cognitive Impairment, Metastatic Malignant Neoplasm in the Brain, Solid Neoplasm
- Interventions
- Whole brain radiation therapy with hippocampal avoidance, Memantine, Whole brain radiation therapy
- Radiation · Drug
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 518 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 212
- States / cities
- Tuscaloosa, Alabama • Gilbert, Arizona • Tucson, Arizona + 172 more
- Conditions
- Hypertension
- Interventions
- Hydrochlorothiazide (HCTZ), Chlorthalidone (CTD)
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 65 Years and older
- Enrollment
- 20,723 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 69
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fayetteville, Arkansas + 64 more
- Conditions
- Electrical Status Epilepticus in Sleep
- Interventions
- ESES treated with clobazam
- Drug
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 2 Years to 21 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • Boston, Massachusetts
- Conditions
- Rett Syndrome
- Interventions
- NGN-401
- Genetic
- Lead sponsor
- Neurogene Inc.
- Industry
- Eligibility
- 3 Years and older · Female only
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Oakland, California • Aurora, Colorado + 10 more
- Conditions
- Suicide
- Interventions
- ACT for Life, Present Centered Therapy
- Behavioral
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 278 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • Battle Creek, Michigan
- Conditions
- Adult Cholangiocarcinoma, Advanced Adult Hepatocellular Carcinoma, BCLC Stage C Adult Hepatocellular Carcinoma, BCLC Stage D Adult Hepatocellular Carcinoma, Hilar Cholangiocarcinoma, Localized Non-Resectable Adult Liver Carcinoma, Recurrent Adult Liver Carcinoma, Recurrent Childhood Liver Cancer, Recurrent Extrahepatic Bile Duct Carcinoma, Recurrent Gallbladder Carcinoma, Stage II Gallbladder Cancer, Stage III Childhood Hepatocellular Carcinoma, Stage IIIA Gallbladder Cancer, Stage IIIB Gallbladder Cancer, Stage IV Childhood Hepatocellular Carcinoma, Stage IV Distal Bile Duct Cancer, Stage IVA Gallbladder Cancer, Stage IVB Gallbladder Cancer, Unresectable Extrahepatic Bile Duct Carcinoma
- Interventions
- Capecitabine, Fluorouracil, Laboratory Biomarker Analysis, Leucovorin Calcium, Trametinib
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 295
- States / cities
- Anchorage, Alaska • Anaheim, California • Auburn, California + 189 more
- Conditions
- Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer
- Interventions
- saracatinib, pharmacogenomic studies, pharmacological study, positron emission tomography, fludeoxyglucose F 18, laboratory biomarker analysis
- Drug · Other · Procedure + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 7
- States / cities
- Scottsdale, Arizona • Aurora, Colorado • Jacksonville, Florida + 4 more
- Conditions
- Contraception
- Interventions
- Etonogestrel 68Mg Implant
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 34 Years · Female only
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Physical Disability
- Interventions
- High-Intensity Rehabilitation plus Mobility (HeRo)
- Other
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Spinal Muscular Atrophy
- Interventions
- nusinersen
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- Not listed
- Enrollment
- 292 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 18
- States / cities
- Los Angeles, California • Palo Alto, California • Aurora, Colorado + 15 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Upadacitinib, Placebo
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 63 Years
- Enrollment
- 1,014 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 132
- States / cities
- Chandler, Arizona • Flagstaff, Arizona • Gilbert, Arizona + 107 more
- Conditions
- Epilepsies, Partial
- Interventions
- ganaxolone
- Drug
- Lead sponsor
- Marinus Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 69 Years
- Enrollment
- 123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 22 more
- Conditions
- Juvenile Spondyloarthritis
- Interventions
- Standard TNFi Therapy, TNFi fixed longer dosing intervals, Stop TNFi treatment
- Other
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 8 Years to 21 Years
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 30
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 27 more